These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 25993209

  • 1. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
    Nowakowski GS, Czuczman MS.
    Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
    [Abstract] [Full Text] [Related]

  • 2. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA, Smith SM.
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.
    Lin P, Medeiros LJ.
    Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diffuse large B-cell lymphoma.
    Li S, Young KH, Medeiros LJ.
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
    Blood; 2009 Jun 11; 113(24):6069-76. PubMed ID: 19380866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Genetics and diffuse large B-Cell lymphoma.
    Niroula R, Butera J.
    R I Med J (2013); 2015 Nov 02; 98(11):23-6. PubMed ID: 26517251
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK, Gascoyne DM, Soilleux EJ, Lyne L, Spearman H, Roncador G, Pedersen LM, Møller MB, Green TM, Banham AH.
    Oncotarget; 2016 Aug 16; 7(33):52940-52956. PubMed ID: 27224915
    [Abstract] [Full Text] [Related]

  • 18. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 19. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G, Wood L, Smith L, Chan JW, Armitage J, Jacobs P.
    Transfus Apher Sci; 2013 Oct 20; 49(2):120-32. PubMed ID: 23942329
    [Abstract] [Full Text] [Related]

  • 20. Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.
    Friedberg JW.
    Hematology Am Soc Hematol Educ Program; 2015 Oct 20; 2015():618-24. PubMed ID: 26637779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.